Literature DB >> 21119692

Autoimmunity, recessive diseases, and gene replacement therapy.

James M Wilson1.   

Abstract

Entities:  

Mesh：

Year:  2010        PMID： 21119692      PMCID： PMC2997601          DOI： 10.1038/mt.2010.253

Source DB:  PubMed          Journal:  Mol Ther        ISSN： 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  8 in total

1.  Dystrophin immunity in Duchenne's muscular dystrophy.

Authors:  Jerry R Mendell; Katherine Campbell; Louise Rodino-Klapac; Zarife Sahenk; Chris Shilling; Sarah Lewis; Dawn Bowles; Steven Gray; Chengwen Li; Gloria Galloway; Vinod Malik; Brian Coley; K Reed Clark; Juan Li; Xiao Xiao; Jade Samulski; Scott W McPhee; R Jude Samulski; Christopher M Walker
Journal:  N Engl J Med       Date:  2010-10-07       Impact factor: 91.245

2.  Recombinant adeno-associated virus vectors induce functionally impaired transgene product-specific CD8+ T cells in mice.

Authors:  Shih-Wen Lin; Scott E Hensley; Nia Tatsis; Marcio O Lasaro; Hildegund C J Ertl
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

3.  Vaccines based on novel adeno-associated virus vectors elicit aberrant CD8+ T-cell responses in mice.

Authors:  Jianping Lin; Yan Zhi; Lauren Mays; James M Wilson
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

4.  Specific T cell receptor gene rearrangements at the site of muscle degeneration in Duchenne muscular dystrophy.

Authors:  E Gussoni; G K Pavlath; R G Miller; M A Panzara; M Powell; H M Blau; L Steinman
Journal:  J Immunol       Date:  1994-11-15       Impact factor: 5.422

5.  Adeno-associated virus-mediated gene transfer to nonhuman primate liver can elicit destructive transgene-specific T cell responses.

Authors:  Guangping Gao; Qiang Wang; Roberto Calcedo; Lauren Mays; Peter Bell; Lili Wang; Luk H Vandenberghe; Rebecca Grant; Julio Sanmiguel; Emma E Furth; James M Wilson
Journal:  Hum Gene Ther       Date:  2009-09       Impact factor: 5.695

6.  Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy.

Authors:  Mark L Brantly; Jeffrey D Chulay; Lili Wang; Christian Mueller; Margaret Humphries; L Terry Spencer; Farshid Rouhani; Thomas J Conlon; Roberto Calcedo; Michael R Betts; Carolyn Spencer; Barry J Byrne; James M Wilson; Terence R Flotte
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-12       Impact factor: 11.205

7.  Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response.

Authors:  Catherine S Manno; Glenn F Pierce; Valder R Arruda; Bertil Glader; Margaret Ragni; John J Rasko; John Rasko; Margareth C Ozelo; Keith Hoots; Philip Blatt; Barbara Konkle; Michael Dake; Robin Kaye; Mahmood Razavi; Albert Zajko; James Zehnder; Pradip K Rustagi; Hiroyuki Nakai; Amy Chew; Debra Leonard; J Fraser Wright; Ruth R Lessard; Jürg M Sommer; Michael Tigges; Denise Sabatino; Alvin Luk; Haiyan Jiang; Federico Mingozzi; Linda Couto; Hildegund C Ertl; Katherine A High; Mark A Kay
Journal:  Nat Med       Date:  2006-02-12       Impact factor: 53.440

8.  Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression.

Authors:  Zejing Wang; Christian S Kuhr; James M Allen; Michael Blankinship; Paul Gregorevic; Jeffrey S Chamberlain; Stephen J Tapscott; Rainer Storb
Journal:  Mol Ther       Date:  2007-04-10       Impact factor: 11.454
  8 in total
  2 in total

1.  Reduced retinal transduction and enhanced transgene-directed immunogenicity with intravitreal delivery of rAAV following posterior vitrectomy in dogs.

Authors:  R F Boyd; S L Boye; T J Conlon; K E Erger; D G Sledge; I M Langohr; W W Hauswirth; A M Komáromy; S E Boye; S M Petersen-Jones; J T Bartoe
Journal:  Gene Ther       Date:  2016-04-07       Impact factor: 5.250

2.  The immune system in Duchenne muscular dystrophy: Friend or foe.

Authors:  S Armando Villalta; Amy S Rosenberg; Jeffrey A Bluestone
Journal:  Rare Dis       Date:  2015-02-23
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.